4-PrO-DMT
4-PrO-DMT.svg
4-PrO-DMT 3D BS.png
Clinical data
Other names4-Propanoyloxy dmt
Identifiers
  • [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] propanoate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H20N2O2
Molar mass260.337 g·mol−1
3D model (JSmol)
  • CCC(=O)OC1=CC=CC2=C1C(=CN2)CCN(C)C
  • InChI=1S/C15H20N2O2/c1-4-14(18)19-13-7-5-6-12-15(13)11(10-16-12)8-9-17(2)3/h5-7,10,16H,4,8-9H2,1-3H3
  • Key:KUOGXPDQORRHED-UHFFFAOYSA-N

4-Propionoxy-N,N-dimethyltryptamine (4-PrO-DMT, or O-Propionylpsilocin) is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is theorized to act as a prodrug for psilocin. It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019.[1]

Recreational use

4-PrO-DMT Crystals
4-PrO-DMT Crystals

Dosage

4-PrO-DMT is reported to be orally active, though its threshold and duration are unstudied.[2]

Effects

The effects of 4-PrO-DMT are broadly comparable to those of other serotonergic psychedelics such as LSD and psilocybin.

[3]

Pharmacology

Pharmacodynamics

4-PrO-DMT is theorized to be a serotonergic psychedelic, and is partial agonist of the 5-HT1D, 5-HT1B and 5-HT1A serotonin receptors.[4]

Similar to 4-AcO-DMT, 4-PrO-DMT is believed to be a pro-drug of psilocin.[5]

Toxicity

Very little data about the toxicity or pharmacology of 4-PrO-DMT is known. Its chemical structure and pharmacological activity are similar to psilacetin, a compound which isn't associated with compulsive use or physical dependence. However, due to lack of research and data, it cannot be definitively concluded that its pharmacological actions in the human body do not differ from those of psilacetin. To date, there have been no reported deaths from 4-PrO-DMT.

See also

References

  1. ^ European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.
  2. ^ Rossouw F (2018-12-06). "Why are Psilocin and Psilocybin Orally Active?". Medium. Retrieved 2023-01-05.
  3. ^ Andersen KA, Carhart-Harris R, Nutt DJ, Erritzoe D (February 2021). "Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies". Acta Psychiatrica Scandinavica. 143 (2): 101–118. doi:10.1111/acps.13249. PMID 33125716. S2CID 226217912.
  4. ^ Celada P, Bortolozzi A, Artigas F (September 2013). "Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research". CNS Drugs. 27 (9): 703–716. doi:10.1007/s40263-013-0071-0. PMID 23757185. S2CID 31931009.
  5. ^ Mashkovsky MD, Yakhontov LN (1969). "Relationships between the chemical structure and pharmacological activity in a series of synthetic quinuclidine derivatives". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques. 13: 293–339. doi:10.1007/978-3-0348-7068-9_6. ISBN 978-3-0348-7070-2. PMID 4391190.
Categories